Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 17:47:15 Source:worldViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at
Next:Election 2024: Biden and Trump bypassed the Commission on Presidential Debates
You may also like
- Philippines blames China for loss of giant clams in disputed shoal and urges environmental inquiry
- Brace yourselves, Married At First Sight is back
- Taylor Swift's father Scott Swift allegedly punched Sydney paparazzo in face
- 100 days since Hamas attacked Israel, triggering war in Gaza
- Why US Catholics are planning pilgrimages in communities across the nation
- Hope new research will help get answers for those with rare disorders
- Call for schools soft drink ban renewed after government implements cellphone ban
- Government rejects Auckland Mayor Wayne Brown's demands over rates, GST
- Red Lobster seeks bankruptcy protection after closing some restaurants